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Liver transplantation 
DELAWIR KAHN and THOMAS STARZL 
INTRODUCTION 
Liver transplantation, the ultimate thera-
peutic option in liver disease, has ceased to 
be an experimental procedure, Indeed, trans-
plantation, which is currently the treatment 
Llt choice for patients with chronic end-stage 
liver disease, should now be part of the 
therapeutic armamentarium of all practicing 
hepatLllogists, 
rhe tirst human liver transplant was 
performed in Denver m 1%3. The earlv years 
were difficult and the overall results poor, 
with only the minority of patients surviving 
for any Significant period of time. However, it 
is noteworthy that nearlv 20% ot patients 
treated before 1'179 are still alive 14 to 24 years 
later. rhe introduction of the new immuno-
suppressive drug cvcIosporme In the I.lte 
I970s saw d dramatic Improvement in the 
results of liver transplantation. rhis led to the 
important NIH Consensus Development 
Conterence m I YH3, where It was decided that 
liver tr:1I1splantation ~houlg no longer bl' 
regarded as an experimental procedure but 
one that merited widespread clinical applica-
tion. The late IYHOs saw .1 phenomenal 
increase in the number of transplant centers 
and the number of patients being trans-
planted, not only in the USA and Europe but 
throughout the world, Indeed, over :WOO liver 
transplants were undertaken in the USA in 
1'189. 
Several factors contributed to the dramJtic 
improvement in the results of liver transplJn-
tation during the 19HOs. The sllrgic.ll proce-
dure becJOle stand.1rdized .1IlU l',111 now be 
performed bv .1!1V cornpl'tel1t Iwp.Jtobili.Hv 
~urgeonK Refinements 111 tlw surgical tl'ch-
nique include the introduction of thl' Vl'no-
venous bvpass, the lise of .1' growth f.Ktor· for 
the v.lscuI.1r .1Il.lstomoses, st.lIlu.1rlii/.ltion of 
the biliarv .1l1astomoSlS .1l1d lllodifil"ltions in 
the donor techl1lque, Bl'ttl'r p.ltil'nt selL-ction, 
the introuuctlon 01 new immunosuppression 
regimens, .1I1d improvl'ments ill org.lIl preser-
vatIOn ".lYe .1Iso (ontnbuted to the lInproved 
rl'sults, 
Manv (cnters .He now .lble to .lchicvl' 1-
vear survival ligures in l'xcess ot 9()% 
providing onlv goou risk pJtients .He treated, 
1'.1til'nts who survIve the first Vl'.H .liter the 
transpl.1I1t may l'xpect .1 i.lVorable long-term 
llutcome with .1 low rate of attrition, 
Liver trallsl'lalltatioll 
INDICATIONS FOR LIVER 
TRANSPLANT A nON 
The indications for orthotopic liver transplan-
tation include chronIC advanced liver disease, 
hepatic malignancy, fulminant hepatic failure 
and metabolic liver disease (Table 27.1). 
Table 27.1 Indications for orthotopic liver trans-
plantation 
Chronic liver disease 
Cholestatic liver disease 
• primarv biliarv cirrhosis 
• pnmarv sclerosln~ cholan~tis 
• biliarvatresla 
Hepatocellular liver disease 
• viral hepatitis 
• alcoholic liver disease 
• drug-induced liver disease 
• autoimmune liver disease 
• cryptogenic cirrhosis 
Vascular disease 
• Hudd-Chiari svndrome 
Hepatic malignancv 
Hepatocellular carcinoma 
CholanpocaTCInoma 
CarcinOid 
Fulminant hepatic tallure 
Viral hepatitis 
Drug-illduced 
Metabolic liver disea,e 
Wilson s disease 
Tvroslnemla 
Alpha-t anlltrvpsm deficiencv 
The chronic liver diseases can be divided 
into those which are predominantlv 
cholestatlc in nature and include primary 
biliarv Cirrhosis, primarv sclerosing cholan-
gitis ,1I1d biliJrY atresia, and those diseases 
which predominantlv iltfect the hepatocytes 
,lnd include chronic viral liver disease, 
chronic drug-induced liver disease, alcoholic 
liver disease .lnd autoimmune liver disease. 
Some patients with the Budd-Chiari 
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syndrome mav also benetit from a liver trz1I1S-
plant. Liver transplantation for hepatic malig-
nancy is a controversial area since milny 01 
these patients die from recurrence of the 
tumor soon after the transplant. On the other 
hand, patients with chronic liver disease with 
an incidental small hepatoma noted in the 
resected liver do well after liver transplantJ-
tion and hJve much the same prognosis .1, 
patients who are transplanted for end-st,lgl' 
liver disease. Some tumors appear to beh,1\'l' 
less aggressivelv. Indeed, patients with fibm-
lamellar tumors and hemanglOendotheliom.1s 
do relatively well after transplantation. 111 
addition, better survival and lower rJtes 01 
recurrence have been reported after livl'r 
transplantation in patients with cirrhosis of 
the liver and J small «5 cm) histologicallv 
non-invasive hepatocellular carcinoma when 
compared with liver resection. In contrJsl, 
cholangiocarcinoma is regarded as a relativl' 
contrai nd ica tion to liver transplan tation 
because of the high rate of recurrence ,lilt! 
poor survival figures. 
Liver transplantation for fulminant hep,ltlL' 
failure is another controversial area. Bec.lUsl' 
of the unpredictable natural historv of thl' 
disease, Illany patients with fulmin,1Il1 
hepatic failure die before a suitable donor 
becomes available. Although a smillI numbl'r 
of patIents in stage 4 coma mily recover with 
medical support onlY, over HO% are likely to 
die as a result of their disease (Chapter 12). 
Thus transplantation should be considered III 
these patients. 
Of great interest to some physicians are the 
v..uious inborn errors of metabolism that .lre 
now potentiallv treatable by liver transplant,l-
tion. I'hese patients can be divided into tho~lD 
where the liver is severelv damaged bv 
cirrhosis, such as in cases of Wilsons glpeK1~lDI 
alpha-l antitrypsin deficiencv and tvropfl1M~1~I 
and the liver transplant is indicated becau!'lc lit 
chromc liver disease. and those patients where 
the liver is morphologically normal although It 
contains a metabolic defect which is damah'lng 
" 
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another svstem. For example. patients with 
familial hypercholesterolemia have normal 
lipid levels after liver transplantation. 
CONTRAINDICA TIONS TO LIVER 
TRANSPLANTATION 
The contraindications to liver transplantation 
(Table 27.2) are being continually revised. 
Certain diseases in which transplantation 
might have previously been precluded or 
strongly discouraged are no longer absolute 
contraindications for transplantation. 
Table 27.2 Contraindications to liver transplantation 
Absolu te contra indications 
Sepsis outside the biliary tree 
Advanced cardiopulmonary disease 
Metastatic hepatic malignancy 
AIDS 
Relative contraindications 
Portal vein thrombOSIS 
Age >hO vears 
Advanced dialvsis-dependent renal disease 
HBsAg pOSItivity 
HlV -pusitive 
Previous upper abdominal surgery 
Cholanh'1UGlrcinoma 
Hvpoxemia with right to lett shunts 
Patients who have active sepsis outside of 
the liver ,1nd patients who have severe 
cardiac or respiratory disease are not consid-
ered as transplant candidates. Metastatic 
malignancv ilnd AIDS are also regarded as 
absolute contraindications. A few centers 
have transplanted patients who are HIV -posi-
tive but without clinical AIDS. VarIous tech-
niques have been devised to circumvent the 
problem of portal vein thrombosis and this is 
no longer a contraindication. Neither is age. 
Indeed. many patients over the age ot 60 
vears have undergone successful orthotopic 
iiver transplantation. Patients with advanced 
chronic renal disease can be subjected to 
Operative procedure 
kidney transplantation in addition to the liver 
transplant. Liver transplantation in patients 
who are hepatitis B surface antigen-positive 
remains controversial because of the high rate 
of recurrent disease after transplantation. 
However. many patients do survive long-
term. Those patients who are HBV-DNA 
negative and those who receive immunopro-
phylaxis ilfter liver transplantation have il 
more tavorJblc prognosis. Upper abdominJI 
surgery. in the form of portacaval shunts or 
major hepatobiliary surgery. ,1dd to the 
complexitv of the transplant procedure. 
Cholangiocarcinoma is .l relative contraindi-
cation because of the high incidence of recur-
rence of the tumor. Hypoxemia with right to 
left shunts is also regarded as a relative 
contraindication. 
TIMING OF LIVER TRANSPLANT A TlON 
One of the Illost difficult ,1spects of liver 
transplantation IS the optimal timing of thl' 
transplant procedure. Many patients with 
chronic ,Idvanced liver dise,lse die while 
awaiting liver transpl,mtation. Furthermore. if 
one wtlits too long bl'lore referring p,ltients 
for liver tr,1I1spl,lIlt,ltioll their gelll'r.ll nmdi-
tlon Illay deterior,lte to .1 pOint wlwrl' till' 
outcome ot the lr<lnspl,lIlt procedure m.lY be 
compromIsed. Thus l',lTly rderral h,lS to bc 
balanccl.i ,Igainsl opl'r.!tivc mortality ,b Wl'l\ 
,IS long-term benl'lit. Cuidelilll's hav\.· becn 
devised to help in detcrmining the best tillle 
for referring patients lor transplantation 
Crable 27.3). I\nv p,ltient with chronic 
,Idvanced liver disc.lse who has ,I malor 
complication such ,lS .1 malor v.!riCC'll bleed. 
in tracta ble .lsci tes. recu rren t b,lCtena I pert-
tonitis or the l.ieveiopment of the hepatorenal 
wnl.irome shoull.i be givl'n the option of .1 
liver transplant. 
OPERATIVE PROCEDURE 
In orthotopiC liver transplantation. the 
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fable 27.3 IndiGltions tor liver transplantation 
Acute liver failure 
• Bilirubin >20mw1 E4MM~mof;1F 
• Prothrombin time> 30 sec above control 
• Progressive encephalopathy ~ grade 3 
Chronic liver disease 
Cholestatic liver disease: 
• Bilirubin> 12mg;1 (200 ~mol;1F 
• Intractable pruritus 
• Advanced bone disease 
Hepatocellular liver disease: 
• Albumm < 2.5W1 
• Hepatic encephalopathv worst grade ~ 3 
• Prolonged prothrombin time 
Factors common to both 
• Hepatorenal syndrome 
• Recurrent bacterial peritonitis 
• Refractory ascites 
• Recurrent biliary sepsis 
• Development of hepatoma 
• Major variceal bleeding 
diseased native organ is removed and 
replaced with a new liver in the most anatom-
ically normal way possible. The technical 
,1spects of the transplant procedure have 
undergone malor refinements over the Years, 
,md have been deScribed in detail else~hereK 
Various techniques have been devised to 
circumvent anomalies ot donor or recipient 
blood vessels. The introduction of the extra-
corporeal venovenous bypass in 1 YH3 to 
decompress the splanchniC and systemic 
venous circulations during the anhepatic 
phase has been one of the most important 
rdinements in the surgical technique. The 
venovenous bypass is used either routinelv or 
selectively in' patients with severe portal 
hvpertension ,1I1d compromised renal func-
tion or in those who fail a trial of cross-
clamping. Reconstruction ot the biliarv tract 
has also become standardized and can be 
done either by connecting the donor and 
reCipient common ducts end-to-end over a 1'-
tube or the common duct of the donor to a 
jejunal limb in a Roux anastomosis. 
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IMMUNOSUPPRESSION 
The introduction of the new immunosuppres_ 
sant agent cyclosporine in the late 1970s led to 
a significant improvement in the results ot 
solid organ transplantation. The search for 
new and more potent immunosuppressive 
drugs continues. Currently most patients 
receive a combination of cyclosporine, steroids 
and azathioprine after liver transplantation. 
Some centers have used a sequential immuno-
suppression regimen where a monoclonal or " 
polyclonal antibody is used for the first 7-1 () 
days and cyclosporine introduced thereattef. 
This is done to minimize the nephrotoxic 
effects of cyclosporine. The new immunosup-
pressant agent FKS06 was discovered in lYH4 
in the northern regions of Japan and has been 
shown, ill vitro, to be many times more potent 
than cyclosporine. These initial findings were 
confirmed, ill vivo, in heart, liver and kidney 
transplants in dogs, rats and primates. FKSOh 
has been shown to be effective as a form ot 
salvage or rescue therapy In patients who 
continue to reject the liver grafts despltl' 
L'Onventional treatment of acute rejection. I Ill' 
initial multicenter trials comparing FK50h 
,1gainst cyclosporine "howed better palll'l1t 
,1Od graft survival in Europe but no differencL' 
in the USA compilations. However, in both 
series there was a different spectrum of side 
effects, less steroid-resistant rejection ,1I1d 
lower steroid usage with FKSOh. Other 
immunosuppressive agents under investiga-
tion include brequinar sodium, dyspergaulin 
,1Od RS61443. 
LIVER PRESERV ATION 
The major advance in liver transplantation III 
the 19HOs was the introductIOn ut ,1 new 
preservation medium, the Wisconsin sulu-
tion. Although livers can be stored for longer 
than 2-1 hours. recent studies have indicated 
that ischemic times of longer than 12-15 
hours are associated with a h'Teater incidence 
i 
of primary non-function as well as delayed 
intrahepatic biliary strictures. However, liver 
transplants can now be performed as an elec-
tive procedure. It has also made it possible to 
increase the size of the donor pool and there-
fore increase the number of liver transplants 
being performed. 
REDUCED-SIZE LIVER TRANSPLANT A-
TION 
The lack of organ donors continues to be a 
major limiting factor in transplantation. This is 
especially true for pediatric patients awaiting 
liver transplantation. To overcome this critical 
shortage of suitable-sized pediatric donors, a 
lobe or segments of an adult liver can be trans-
planted into a pediatric recipient. Mortality 
rates for children awaiting liver transplanta-
tion are now almost negligible. The results of 
reduced-size liver transplantation are as );ood 
as intact livers. In contrast, the results of split 
liver transplantation are poorer. 
LIVING RELATED LIVER 
TRANSPLANT A nON 
The number of live related liver tr,msplants 
,1nd the number of centers performing this 
Recommended reading 
procedure have increased significantly in 
recent years. Graft and patient survival have 
been as );ood as intact liver transplantation. 
The risk to the donor has been acceptable 
with only one mortality documented thus far. 
The major advantage is that the transplant 
can be undertaken electively with the patient 
in optimal condition. 
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